Keryx (KERX -3.6%) notes that the Taxpayer Relief Act delays by two years, until January 2016,...

|About: Keryx Biopharmaceuticals,... (KERX)|By:, SA News Editor

Keryx (KERX -3.6%) notes that the Taxpayer Relief Act delays by two years, until January 2016, the inclusion of oral-only dialysis-related drugs in the money that Medicare pays facilities in a single bundle for dialysis treatment. Keryx CEO Ron Bentsur says this is a good thing for the firm's Zerenex drug, although investors don't seem to be convinced. (PR)